[{"id":"2f8a0b9b-5eb1-43c3-93e2-5b9c6b8ed148","acronym":"","url":"https://clinicaltrials.gov/study/NCT02048488","created_at":"2021-01-18T09:24:44.946Z","updated_at":"2024-07-02T16:37:01.267Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT02048488","lead_sponsor":"Tesaro, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e belizatinib (TSR-011)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-03-26"}]